Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Cytotherapy. 2010 Oct;12(6):807–817. doi: 10.3109/14653249.2010.491821

Figure 1.

Figure 1

Inhibition of p38MAPK directs differentiation of hEB into hCM in a developmental stage- and dose-specific manner. (A) hEB were incubated in the presence of 10 μM SB203580 in culture during the indicated days. Treatment during days 2–6 resulted in an increase in the number of beating hCM at day 21, with the maximal effect seen (c. 2.3-fold) with treatment during days 4–6. Data shown are mean percentage ± SEM (n = 5; refers to separate experiments in all figure legends). *P < 0.01, **P < 0.0001. (B) hEB were cultured in the presence of 5, 10 or 20 μM SB203580 during days 4–6 days of differentiation. Treatment with 5–10 μM SB203580 resulted in an increase in the number of beating hCM at day 21, with the maximal effect seen (c. 2.3-fold) with 5 μM. Data shown are mean percentage ± SEM (n = 5). *P < 0.01.